<unk>  is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that is FDA approved for the treatment of adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.   Common adverse reactions include urinary tract infections, female genital mycotic infections, hypoglycemia, hypotension.
Empagliflozin
Canagliflozin
Linagliptin
Dapagliflozin
Liraglutide
Vildagliptin
Pioglitazone
Exenatide